HealthInvest Partners AB Has $1.37 Million Stock Position in Mereo BioPharma Group plc (NASDAQ:MREO)

HealthInvest Partners AB lifted its position in Mereo BioPharma Group plc (NASDAQ:MREO) by 95.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 390,000 shares of the company’s stock after acquiring an additional 190,000 shares during the period. HealthInvest Partners AB owned about 0.25% of Mereo BioPharma Group worth $1,373,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Janus Henderson Group PLC grew its position in Mereo BioPharma Group by 56.7% during the 3rd quarter. Janus Henderson Group PLC now owns 12,345,866 shares of the company’s stock worth $50,865,000 after purchasing an additional 4,464,984 shares in the last quarter. Frazier Life Sciences Management L.P. boosted its position in shares of Mereo BioPharma Group by 15.8% in the third quarter. Frazier Life Sciences Management L.P. now owns 5,097,779 shares of the company’s stock worth $20,952,000 after buying an additional 696,408 shares during the period. Acuta Capital Partners LLC grew its holdings in shares of Mereo BioPharma Group by 86.2% during the third quarter. Acuta Capital Partners LLC now owns 1,260,700 shares of the company’s stock valued at $5,181,000 after buying an additional 583,700 shares in the last quarter. Polar Asset Management Partners Inc. raised its position in Mereo BioPharma Group by 36.0% during the third quarter. Polar Asset Management Partners Inc. now owns 198,300 shares of the company’s stock valued at $815,000 after buying an additional 52,500 shares during the period. Finally, Fred Alger Management LLC lifted its stake in Mereo BioPharma Group by 108.1% in the 3rd quarter. Fred Alger Management LLC now owns 102,582 shares of the company’s stock worth $422,000 after acquiring an additional 53,278 shares in the last quarter. Institutional investors and hedge funds own 62.83% of the company’s stock.

Mereo BioPharma Group Trading Down 0.5 %

NASDAQ MREO opened at $2.86 on Monday. Mereo BioPharma Group plc has a 12-month low of $2.78 and a 12-month high of $5.02. The company has a 50 day moving average price of $3.21 and a two-hundred day moving average price of $3.81.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the company. Jefferies Financial Group initiated coverage on Mereo BioPharma Group in a research note on Friday, December 6th. They set a “buy” rating and a $7.00 target price on the stock. Lifesci Capital started coverage on shares of Mereo BioPharma Group in a research report on Tuesday, December 24th. They set an “outperform” rating and a $10.00 price objective on the stock. Needham & Company LLC reiterated a “buy” rating and issued a $7.00 target price on shares of Mereo BioPharma Group in a research report on Monday, January 13th. Finally, Cantor Fitzgerald raised shares of Mereo BioPharma Group to a “strong-buy” rating in a research note on Sunday, December 8th. Four analysts have rated the stock with a buy rating and three have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Mereo BioPharma Group presently has an average rating of “Buy” and a consensus price target of $7.83.

Mereo BioPharma Group Company Profile

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors.